Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Clinical Lung Cancer|February 27, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasYusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, et al.
International Journal of Cancer|June 15, 2019
Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancerYuta Takashima, Eiki Kikuchi, Junko Kikuchi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2011
Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancerJun Sakakibara-Konishi, Satoshi Oizumi, Ichiro Kinoshita, et al.
Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2020
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancerTetsuaki Shoji, Eiki Kikuchi, Junko Kikuchi, et al.
Cell Cycle (Georgetown, Tex.)|August 18, 2023
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancerKosuke Tsuji, Eiki Kikuchi, Yuta Takashima, et al.
Respiratory Medicine Case Reports|May 1, 2026
Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case reportChisa Murayama, Yasuyuki Ikezawa, Chihiro Shiiya, et al.
Respiratory Investigation|March 22, 2025
Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapyDaisuke Morinaga, Jun Sakakibara-Konishi, Yasutaka Kawai, et al.
Clinical Lung Cancer|March 17, 2018
Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsYuta Takashima, Jun Sakakibara-Konishi, Yutaka Hatanaka, et al.
Cancer Science|November 22, 2022
Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancerHirofumi Takahashi, Jun Sakakibara-Konishi, Megumi Furuta, et al.
Pageof 10